LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

33.27

Buy Sell

Overview

Share price change

24h

Current

Min

32.83

Max

33.56

Key metrics
By Trading Economics
Income	11M 51M
Sales	39M 239M
P/E Sector Avg	10.722 106.172
EPS	1.08
Profit margin	21.242
Employees	268
EBITDA	14M 73M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+35.33% upside

Market Stats
By TradingEconomics
Market Cap	270M 2B
Previous open	33.27
Previous close	33.27

News Sentiment

By Acuity

55%

45%

102 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 lis 2025, 23:07 UTC

Market Talk

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 lis 2025, 22:22 UTC

Market Talk

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 lis 2025, 22:08 UTC

Market Talk

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 lis 2025, 21:57 UTC

Earnings

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 lis 2025, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

20 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 lis 2025, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 lis 2025, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

20 lis 2025, 21:31 UTC

Earnings

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 lis 2025, 21:23 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 lis 2025, 21:07 UTC

Earnings

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 lis 2025, 21:06 UTC

Earnings

Webull 3Q Rev $156.9M >BULL

20 lis 2025, 21:06 UTC

Earnings

Webull 3Q EPS 7c >BULL

20 lis 2025, 21:05 UTC

Earnings

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 lis 2025, 21:04 UTC

Earnings

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 lis 2025, 21:04 UTC

Earnings

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 lis 2025, 21:04 UTC

Earnings

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 lis 2025, 21:00 UTC

Earnings

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 lis 2025, 21:00 UTC

Earnings

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 lis 2025, 21:00 UTC

Earnings

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 lis 2025, 21:00 UTC

Earnings

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 lis 2025, 21:00 UTC

Earnings

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 lis 2025, 21:00 UTC

Earnings

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 lis 2025, 21:00 UTC

Earnings

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 lis 2025, 21:00 UTC

Earnings

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 lis 2025, 21:00 UTC

Earnings

Intuit 1Q Consumer Rev $894M

20 lis 2025, 21:00 UTC

Earnings

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 lis 2025, 21:00 UTC

Earnings

Intuit Backs FY26 Guidance

20 lis 2025, 21:00 UTC

Earnings

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 lis 2025, 21:00 UTC

Earnings

Intuit 1Q Global Business Solutions Rev $3B

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

35.33% upside

12 Months Forecast

Average 46 USD 35.33%

High 62 USD

Low 32 USD

Based on 10 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

102 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.